8-K: AdaptHealth Sells Diabetes Business for $235M

AdaptHealth Corp. has entered into a definitive agreement to divest its Diabetes Health business to Cardinal Health for $235 million in cash.

Summary

• AdaptHealth Corp. has signed an asset purchase agreement to sell its Diabetes Health business to RGH Enterprises, LLC, a subsidiary of Cardinal Health, Inc.
• The sale price is $235.0 million in cash, subject to customary post-closing adjustments for net working capital.
• The transaction is expected to close after regulatory review, including under the Hart-Scott-Rodino Antitrust Improvements Act.
• This divestiture is part of AdaptHealth's multi-year strategy to focus on its core sleep and respiratory businesses.
• The company expects this move to improve its revenue growth profile and adjusted EBITDA margins.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the divestiture allows AdaptHealth to focus on its core, higher-growth segments and improve its financial flexibility.

Positives

• Divestiture of the Diabetes Health business for $235 million in cash provides capital flexibility.
• The sale allows AdaptHealth to focus on core sleep and respiratory businesses where it has a stronger competitive position.
• The transaction is expected to accelerate AdaptHealth's deleveraging trajectory and strengthen its balance sheet.
• The company anticipates an improved revenue growth profile and adjusted EBITDA margins on a go-forward basis.

Negatives

• The transaction is subject to customary closing conditions, including regulatory review.
• The company will provide a comprehensive update on financial and guidance implications on its second quarter earnings call.

Risks

• The transaction is subject to regulatory review under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
• The company has agreed to certain restrictive covenants, including a four-year non-competition covenant in North America.
• The purchase agreement may be terminated under certain circumstances, including failure to obtain antitrust clearance, which could result in a termination fee.

Future Outlook

AdaptHealth expects the divestiture to improve its revenue growth profile and adjusted EBITDA margins, and to provide capital flexibility for reinvestment in core businesses and debt reduction.

Management Comments

• "The divestiture of our Diabetes Health business is the latest and most significant step in a deliberate, multi-year effort to focus AdaptHealth on our core businesses where we have the strongest competitive position and the clearest path to growth."
• "Over the past two years, we have systematically reshaped our portfolio around our core sleep, respiratory and supporting HME business lines, where we cross the threshold of the home to deliver clinical value to patients."
• "We are confident that in Cardinal Health, Diabetes Health is going to an owner that has the scale and operational capabilities required to realize the asset's full potential."
• "For AdaptHealth, this transaction allows us to redeploy capital toward our core strengths, further strengthen our balance sheet, and accelerate our pursuit of the compelling growth opportunities ahead of us in sleep and respiratory care."

Industry Context

StockSavvy.ai notes that this divestiture aligns with a broader trend in the healthcare sector where companies are streamlining operations and focusing on core competencies to enhance efficiency and profitability. By divesting its Diabetes Health business, AdaptHealth is positioning itself to capitalize on growth opportunities in the sleep and respiratory care markets, which are experiencing significant demand.

Stakeholder Impact

• Shareholders: Potential for increased focus on core, higher-growth segments and improved financial metrics may lead to positive stock performance.
• Employees: Employees of the Diabetes Health business will transition to Cardinal Health, with terms of employment to be detailed.
• Customers: Patients of the Diabetes Health business will be served by Cardinal Health, which is expected to have greater scale and operational capabilities.
• Suppliers: Suppliers to the Diabetes Health business will now engage with Cardinal Health.

Next Steps

• Completion of regulatory review, including Hart-Scott-Rodino Antitrust Improvements Act.
• Closing of the transaction.
• AdaptHealth to provide a comprehensive update on financial and guidance implications on its second quarter 2026 earnings call.

Key Dates

Recommendation

The divestiture is a strategic move that should benefit AdaptHealth in the long term by allowing it to focus on its core businesses and improve its financial health. However, the immediate impact on share price is uncertain, and the company is still in the process of reshaping its portfolio. Therefore, a 'hold' recommendation is appropriate pending further clarity on the financial implications and the execution of its go-forward strategy.

Keywords

AdaptHealth, Cardinal Health, Asset Purchase Agreement, Divestiture, Diabetes Health Business, Healthcare, Medical Devices, HME